Literature DB >> 26405778

Extension of organized cervical cancer screening programmes in Italy and their process indicators, 2011-2012 activity.

Guglielmo Ronco1, Pamela Giubilato, Francesca Carozzi, Giovanni Maia, Paolo Giorgi Rossi, Marco Zappa.   

Abstract

Italian national guidelines recommend regional implementation of organized screening programmes for cervical cancer. As we have been doing since 1998, we collected aggregated tables of data from Italian organized cervical screening programmes in order to centrally compute process indicators. Data on women invited during 2011 and 2012 and screened up to April of the subsequent year were considered. In 2012, the target population of Italian organized screening programmes included 14,497,207 women, corresponding to 87.3% of Italian women aged 25-64 years. Compliance to invitation was 41.2%in 2011 and 40.8%in 2012, with a strong decreasing North-South trend. However, it should be considered that many women are screened outside any organized programmes. In 2012, of the women screened, 3.5% were referred for repeat cytology and 71.1% of them complied; 2.4% of screened women were referred to colposcopy. Compliance with colposcopy referral was 85.3%among women referred because of ASC-US or more severe cytology and 90.4% among those referred because of HSIL or more severe cytology. The positive predictive value (PPV) of referral because of ASC-US or more severe cytology for CIN2 or more severe histology was 16.9%. The unadjusted detection rate of CIN2 or more severe histology was 3.4 per 1,000 screened women (3.6 standardized on the Italian population, truncated 25-64). CIN2 or more severe histology was detected in 64.6% of colposcopies classified as grade 2 or higher. Of all colposcopies during which a CIN2 or more severe histology was obtained, 33.6% were classified as grade 2 or higher. Follow-up only was recommended to 81.7% of women with CIN1. Excision by radio-frequency device was the most common treatment for women with CIN2 (52.8%) and CIN3 (57.0%). However 0.4% of all CIN2 and 2.3% of all CIN3 had hysterectomy.

Entities:  

Mesh:

Year:  2015        PMID: 26405778

Source DB:  PubMed          Journal:  Epidemiol Prev        ISSN: 1120-9763            Impact factor:   1.901


  5 in total

1.  Cervical cancer screening guidelines and screening practices in 11 countries: A systematic literature review.

Authors:  Wei Wang; Emanuele Arcà; Anushua Sinha; Kristina Hartl; Natalie Houwing; Smita Kothari
Journal:  Prev Med Rep       Date:  2022-05-08

2.  Clinical relevance of partial HPV16/18 genotyping in stratifying HPV-positive women attending routine cervical cancer screening: a population-based cohort study.

Authors:  S Gori; J Battagello; D Gustinucci; C Campari; M Zorzi; H Frayle; B Passamonti; G Sartori; S Bulletti; C Fodero; E Cesarini; R Faggiano; A Del Mistro
Journal:  BJOG       Date:  2021-01-12       Impact factor: 6.531

3.  HPV prevalence and risk of pre-cancer and cancer in regular immigrants in Italy: results from HPV DNA test-based screening pilot programs.

Authors:  Cinzia Campari; Chiara Fedato; Alessio Petrelli; Manuel Zorzi; Carla Cogo; Adele Caprioglio; Federica Gallo; Livia Giordano; Serena Domenighini; Luigi Pasquale; Sonia Prandi; Marco Zappa; Paolo Giorgi Rossi
Journal:  Infect Agent Cancer       Date:  2015-05-07       Impact factor: 2.965

4.  Cervical cancer prevention: An Italian scenario between organised screening and human papillomaviruses vaccination.

Authors:  Maria G Cappelli; Francesca Fortunato; Silvio Tafuri; Sara Boccalini; Paolo Bonanni; Rosa Prato; Domenico Martinelli
Journal:  Eur J Cancer Care (Engl)       Date:  2018-09-04       Impact factor: 2.520

5.  Geographical and socioeconomic differences in uptake of Pap test and mammography in Italy: results from the National Health Interview Survey.

Authors:  Alessio Petrelli; Paolo Giorgi Rossi; Lisa Francovich; Barbara Giordani; Anteo Di Napoli; Marco Zappa; Concetta Mirisola; Lidia Gargiulo
Journal:  BMJ Open       Date:  2018-09-19       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.